|Bid||7.40 x 900|
|Ask||7.99 x 800|
|Day's Range||7.55 - 8.09|
|52 Week Range||5.34 - 47.86|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||20.00|
A look at the shareholders of Scopus BioPharma Inc. ( NASDAQ:SCPS ) can tell us which group is most powerful...
Scopus BioPharma Inc. (Nasdaq: "SCPS") today announced the finalization of arrangements for the completion of the investigational new drug ("IND") package for the company's lead drug candidate and its submission to the United States Food and Drug Administration ("FDA"). The IND submission is expected in Q2 2021.
Scopus BioPharma Inc. (Nasdaq: SCPS) today announced the closing of the underwriters' over-allotment option in full, bringing total follow-on public offering proceeds to $10.35 million.